ImmuneOnco Biopharmaceuticals (Shanghai) Inc. released its Monthly Return for Equity Issuer covering April 2026. The filing shows no change in either registered share capital or issued shares during the period, while the company affirmed full compliance with Hong Kong’s minimum public-float rules.

Total registered share capital remained at RMB 431.51 million, split between 420.48 million H-shares listed on the Stock Exchange of Hong Kong and 11.03 million unlisted domestic shares, each with a par value of RMB 1. No new shares were issued, cancelled or repurchased, and the company held zero treasury shares at month-end.

For its Hong Kong-listed H-share class, ImmuneOnco confirmed adherence to the Main Board’s 25% minimum public-float threshold. Executive Director and Joint Company Secretary Guan Mei signed the submission on 7 May 2026.